share_log

Q2 2023 Earnings Estimate for Catalent, Inc. Issued By Jefferies Financial Group (NYSE:CTLT)

Q2 2023 Earnings Estimate for Catalent, Inc. Issued By Jefferies Financial Group (NYSE:CTLT)

2 年第二季富瑞金融集團(紐約證券交易所代碼:CTLT)發布的加泰倫特股份有限公司收益估計
Defense World ·  2023/01/26 02:36

Catalent, Inc. (NYSE:CTLT – Get Rating) – Analysts at Jefferies Financial Group upped their Q2 2023 EPS estimates for shares of Catalent in a report released on Tuesday, January 24th. Jefferies Financial Group analyst D. Windley now expects that the company will earn $0.71 per share for the quarter, up from their previous estimate of $0.70. The consensus estimate for Catalent's current full-year earnings is $2.93 per share. Jefferies Financial Group also issued estimates for Catalent's Q3 2023 earnings at $0.86 EPS.

Catalent,Inc.(紐約證券交易所代碼:CTLT-GET Rating)-在1月24日星期二發佈的一份報告中,傑富瑞金融集團的分析師上調了對Catalent股票2023年第二季度每股收益的預期。傑富瑞金融集團分析師D.Windley現在預計,該公司本季度每股收益為0.71美元,高於此前預期的0.70美元。對Catalent目前全年收益的普遍預期為每股2.93美元。傑富瑞金融集團還發布了對Catalent 2023年第三季度每股收益的估計為0.86美元。

Get
到達
Catalent
Catalent
alerts:
警報:

A number of other equities analysts also recently issued reports on CTLT. TheStreet downgraded shares of Catalent from a "b-" rating to a "c+" rating in a research note on Friday, October 28th. Bank of America cut shares of Catalent from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $125.00 to $60.00 in a report on Wednesday, November 2nd. Argus cut shares of Catalent from a "buy" rating to a "hold" rating in a report on Monday, November 7th. Royal Bank of Canada cut their price objective on shares of Catalent from $125.00 to $73.00 and set an "outperform" rating for the company in a report on Wednesday, November 2nd. Finally, Morgan Stanley cut their price objective on shares of Catalent from $120.00 to $81.00 and set an "overweight" rating for the company in a report on Thursday, November 3rd. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $92.40.

其他一些股票分析師最近也發佈了關於CTLT的報告。華爾街在10月28日星期五的一份研究報告中將Catalent的股票評級從“b-”下調至“c+”。美國銀行在11月2日(週三)的一份報告中將卡特倫特的股票評級從買入下調至中性,並將該股的目標價從125.00美元下調至60美元。在11月7日星期一的一份報告中,Argus將Catalent的股票評級從“買入”下調至“持有”。11月2日,加拿大皇家銀行在一份報告中將卡特倫特股票的目標價從125.00美元下調至73.0美元,併為該公司設定了“跑贏大盤”的評級。最後,摩根士丹利在11月3日週四的一份報告中將加泰羅蘭股票的目標價從120.00美元下調至81.00美元,併為該公司設定了“增持”評級。一位研究分析師對該股的評級為賣出,三位分析師給出了持有評級,五位分析師給出了該公司股票的買入評級。根據MarketBeat.com的數據,該股目前的普遍評級為持有,平均目標價為92.40美元。

Catalent Price Performance

催化劑的性價比

Shares of CTLT stock opened at $50.16 on Wednesday. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.86 and a quick ratio of 2.08. The company has a market capitalization of $9.03 billion, a P/E ratio of 21.44, a P/E/G ratio of 3.63 and a beta of 1.24. The company's 50-day simple moving average is $46.33 and its two-hundred day simple moving average is $71.89. Catalent has a one year low of $40.69 and a one year high of $115.33.
週三,CTLT的股票開盤報50.16美元。該公司的債務權益比為0.87,流動比率為2.86,速動比率為2.08。該公司市值為90.3億美元,市盈率為21.44倍,市盈率為3.63倍,貝塔係數為1.24。該公司50日簡單移動均線切入位在46.33美元,200日簡單移動均線切入位在71.89美元。Catalent的一年低點為40.69美元,一年高位為115.33美元。

Catalent (NYSE:CTLT – Get Rating) last posted its quarterly earnings data on Tuesday, November 1st. The company reported $0.25 earnings per share for the quarter, missing analysts' consensus estimates of $0.49 by ($0.24). The firm had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.06 billion. Catalent had a return on equity of 12.55% and a net margin of 8.83%.

Catalent(NYSE:CTLT-GET Rating)最近一次公佈季度收益數據是在11月1日星期二。該公司公佈本季度每股收益為0.25美元,低於分析師普遍預期的0.49美元(0.24美元)。該公司本季度營收為10.2億美元,高於分析師預期的10.6億美元。Catalent的股本回報率為12.55%,淨利潤率為8.83%。

Insiders Place Their Bets

內部人士下注

In other Catalent news, insider Ricky Hopson sold 643 shares of the business's stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $49.36, for a total transaction of $31,738.48. Following the completion of the transaction, the insider now owns 16,452 shares in the company, valued at approximately $812,070.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Manja Boerman sold 780 shares of the business's stock in a transaction on Monday, December 5th. The shares were sold at an average price of $51.70, for a total value of $40,326.00. Following the completion of the sale, the insider now directly owns 15,860 shares of the company's stock, valued at $819,962. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Ricky Hopson sold 643 shares of the business's stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $49.36, for a total transaction of $31,738.48. Following the completion of the sale, the insider now directly owns 16,452 shares of the company's stock, valued at $812,070.72. The disclosure for this sale can be found here. Insiders sold 3,874 shares of company stock worth $233,414 in the last 90 days. Corporate insiders own 0.58% of the company's stock.

在加泰羅尼亞的其他消息中,內部人士裏奇·霍普森在1月23日星期一的一筆交易中出售了643股該公司的股票。這些股票的平均價格為49.36美元,總成交額為31,738.48美元。交易完成後,這位內部人士現在擁有該公司16,452股股票,價值約812,070.72美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可在此超鏈接。在相關新聞中,內部人士Manja Boerman在12月5日星期一的一次交易中出售了780股該公司的股票。這些股票的平均價格為51.70美元,總價值為40,326.00美元。出售完成後,這位內部人士現在直接持有該公司15,860股股票,價值819,962美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過此超鏈接。此外,內部人士裏奇·霍普森在1月23日星期一的一次交易中出售了643股該公司的股票。這些股票的平均價格為49.36美元,總成交額為31,738.48美元。出售完成後,這位內部人士現在直接持有該公司16,452股股票,價值812,070.72美元。關於這次銷售的披露可以找到這裏。在過去的90天裏,內部人士出售了3874股公司股票,價值233,414美元。企業內部人士持有該公司0.58%的股份。

Institutional Investors Weigh In On Catalent

機構投資者看好Catalent

A number of institutional investors and hedge funds have recently bought and sold shares of CTLT. Tokio Marine Asset Management Co. Ltd. increased its stake in shares of Catalent by 22.5% during the second quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,043 shares of the company's stock worth $326,000 after acquiring an additional 558 shares during the period. US Bancorp DE grew its position in Catalent by 1.4% during the third quarter. US Bancorp DE now owns 19,237 shares of the company's stock worth $1,392,000 after buying an additional 272 shares during the period. Mitsubishi UFJ Trust & Banking Corp grew its position in Catalent by 12.0% during the second quarter. Mitsubishi UFJ Trust & Banking Corp now owns 90,954 shares of the company's stock worth $9,759,000 after buying an additional 9,723 shares during the period. Illinois Municipal Retirement Fund grew its position in Catalent by 88.1% during the second quarter. Illinois Municipal Retirement Fund now owns 6,028 shares of the company's stock worth $647,000 after buying an additional 2,824 shares during the period. Finally, Private Advisor Group LLC grew its position in Catalent by 98.5% during the second quarter. Private Advisor Group LLC now owns 5,870 shares of the company's stock worth $630,000 after buying an additional 2,913 shares during the period. 99.38% of the stock is owned by hedge funds and other institutional investors.

一些機構投資者和對衝基金最近買賣了CTLT的股票。東京海上資產管理公司在第二季度增持了22.5%的Catalent股票。東京海上資產管理有限公司在此期間增持了558股,目前持有該公司3,043股股票,價值326,000美元。US Bancorp DE在第三季度增加了1.4%的Catalent頭寸。US Bancorp DE現在擁有19,237股該公司股票,價值1,392,000美元,在此期間又購買了272股。三菱UFJ信託銀行(Mitsubishi UFJ Trust&Banking Corp)第二季度在Catalent的頭寸增加了12.0%。三菱UFJ信託銀行(Mitsubishi UFJ Trust&Banking Corp)目前持有90,954股該公司股票,價值9,759,000美元,在此期間又購買了9,723股。伊利諾伊市退休基金在第二季度將其在Catalent的頭寸增加了88.1%。伊利諾伊州市政退休基金現在擁有該公司6,028股股票,價值647,000美元,在此期間又購買了2,824股。最後,Private Advisor Group LLC在第二季度將其在Catalent的頭寸增加了98.5%。Private Advisor Group LLC在此期間又購買了2,913股,現在擁有5870股該公司股票,價值630,000美元。99.38%的股票由對衝基金和其他機構投資者持有。

Catalent Company Profile

Catalent公司簡介

(Get Rating)

(獲取評級)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Catalent公司及其子公司在全球範圍內開發和製造藥物、基於蛋白質的生物製劑、細胞和基因療法以及消費者保健產品的解決方案。軟凝膠和口腔技術部門提供用於一系列客户產品的軟膠囊的配方、開發和製造服務,如處方藥、非處方藥、膳食補充劑、單位劑量化粧品和動物保健藥物製劑。

Recommended Stories

推薦故事

  • Get a free copy of the StockNews.com research report on Catalent (CTLT)
  • AMD Is Still One Of The Best Semiconductor Stocks Out There
  • Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
  • Is The Bottom In For Cyber-Security Stocks?
  • Union Pacific, Norfolk Southern Pull into Buying Zone
  • Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
  • 免費獲取StockNews.com關於Catalent的研究報告(CTLT)
  • AMD仍是市面上最好的半導體股票之一
  • 兩大股利大王:強生還是雅培?
  • 網絡安全類股已經見底了嗎?
  • 聯合太平洋,諾福克南方進入購買區
  • 柔順治療公司的差距增加了34%:未來還會有更多的好處嗎?

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.

接受《Catalent Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Catalent和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論